|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
11/6/2012 7:49:09 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights. “The highlights of this quarter include the positive results we reported in our clinical programs and our continued execution on our ‘Alnylam 5x15’ product strategy. Specifically, we reported positive data from a Phase I study and continued enrollment in our Phase II study of ALN-TTR02. We also showed encouraging pre-clinical data in programs using our GalNAc conjugate delivery platform that enables subcutaneous administration of RNAi therapeutics; these include ALN-TTRsc for the treatment of ATTR and ALN-AT3 for the treatment of hemophilia. Finally, we were pleased to report complete results from a Phase IIb trial of ALN-RSV01 for the treatment of respiratory syncytial virus infection in lung transplant patients,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “Continued execution on our ‘Alnylam 5x15’ product strategy remains our core focus, and we aim to complete our Phase II trial for ALN-TTR02 in mid-2013 and initiate our Phase III trial by the end of 2013. In addition, we expect to file an IND for ALN-TTRsc by end of this year and an IND for ALN-AT3 by mid-2013. With our recent accomplishments in our pipeline efforts, we have strengthened confidence that we can advance RNAi therapeutics toward genetically defined targets for diseases that currently have limited treatment options for patients and their caregivers.”
|
|
|
|
|
|
|
|
|
|
|